NCT03343652View on ClinicalTrials.gov

A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin's Lymphoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 27, 2017

Primary Completion Date

March 27, 2019

Study Completion Date

March 27, 2020

Conditions
Hodgkin's Lymphoma
Interventions
DRUG

Nivolumab

3 mg/kg IV infusion on day 1,14 up to 3 cycles

DRUG

Bendamustine Hydrochloride

90 mg/kg IV infusion on day 1 up to 3 cycles

Trial Locations (1)

197089

First Pavlov State Medical University of St. Petersburg, Saint Petersburg

All Listed Sponsors
lead

St. Petersburg State Pavlov Medical University

OTHER

NCT03343652 - A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter